-
-
No events on calendar for this bill.
-
Representative Wayne Sasser(R)
Representative Kristin Baker, M.D.(R)
Representative Donna McDowell White(R)
Representative Larry W. Potts(R)
Representative Jay Adams(R)
Representative Cynthia Ball(D)
Representative William D. Brisson(R)
Representative Gloristine Brown(D)
Representative Allen Buansi(D)
Representative Maria Cervania(D)
Representative Mike Clampitt(R)
Representative Carla D. Cunningham(D)
Representative Allison A. Dahle(D)
Representative Jimmy Dixon(R)
Representative Rosa U. Gill(D)
Representative Wesley Harris, PhD(D)
Representative Zack Hawkins(D)
Representative Frances Jackson, PhD(D)
Representative Joe John(D)
Representative Donny Lambeth(R)
Representative Carolyn G. Logan(D)
Representative Marvin W. Lucas(D)
Representative Jeffrey C. McNeely(R)
Representative Charles W. Miller(R)
Representative Marcia Morey(D)
Representative Ben T. Moss, Jr.(R)
Representative Howard Penny, Jr.(R)
Representative Joseph Pike(R)
Representative Dennis Riddell(R)
Representative Frank Sossamon(R)
Representative Diamond Staton-Williams, RN, BSN, MHA(D)
Representative Julie von Haefen(D)
Representative Bill Ward(R)
Representative Diane Wheatley(R)
Representative Shelly Willingham(D)
Representative Michael H. Wray(D)
Representative Jeff Zenger(R)
-
Re-ref to Health Care. If fav, re-ref to Rules and Operations of the SenateSenate | 2023-09-14Withdrawn From ComSenate | 2023-09-14Ref To Com On Rules and Operations of the SenateSenate | 2023-04-05Passed 1st ReadingSenate | 2023-04-05Regular Message Received From HouseSenate | 2023-04-05Regular Message Sent To SenateHouse | 2023-04-05Passed 3rd ReadingHouse | 2023-04-04Added to CalendarHouse | 2023-04-04Cal Pursuant Rule 36(b)House | 2023-04-04Reptd Fav Com Sub 2House | 2023-04-04Re-ref Com On Rules, Calendar, and Operations of the HouseHouse | 2023-03-21Reptd Fav Com SubstituteHouse | 2023-03-21Ref to the Com on Health, if favorable, Rules, Calendar, and Operations of the HouseHouse | 2023-03-08Passed 1st ReadingHouse | 2023-03-08FiledHouse | 2023-03-07
-
Passed 2nd ReadingHouse | 2023-04-04 | PASS: 114-0
-
CONTROLLED SUBSTANCES
HEALTH EDUCATION
HEALTH SERVICES
OCCUPATIONS
PHARMACEUTICALS
PHARMACISTS & PHARMACIES
PUBLIC
PUBLIC HEALTH
PATIENT RIGHTS
-
90 (Chapters); 90-12.8 (Sections)
-
No counties specifically cited.
-
-
-
H287: Educate Patients About Opioid Antagonists. Latest Version
Session: 2023 - 2024
AN ACT requiring health care practitioners and pharmacists to educate patients with prescriptions for opioid pain medications and medications to treat opioid use disorder about the potential dangers of opioids, overdose prevention, and the availability and use of opioid antagonists to prevent overdose deaths.
The General Assembly of North Carolina enacts:
SECTION 1. Article 1 of Chapter 90 of the General Statutes is amended by adding a new section to read:
§ 90‑12.8. Requirement to provide opioid antagonist education.
(a) Consistent with the federal Food and Drug Administration's labeling requirements for opioid pain medication and medication to treat opioid use disorder announced in its Drug Safety Communication dated July 23, 2020, a practitioner as defined in G.S. 90‑87(22) shall do all of the following when issuing a prescription for a Schedule II controlled substance described in G.S. 90‑90(1):
(1) Provide information regarding all of the following to each patient receiving the prescription:
a. The potential dangers of opioids.
b. Overdose prevention.
c. The availability and use of a drug approved by the federal Food and Drug Administration as an opioid antagonist for the complete or partial reversal of opioid‑induced respiratory depression.
(2) Provide the information described in sub‑subdivisions (1)a. through (1)c. of this subsection to one or more persons if designated by the patient receiving the prescription or, for a patient who is a minor, to the minor's parent, guardian, or person standing in loco parentis.
(b) When dispensing a Schedule II controlled substance described in G.S. 90‑90(1), a pharmacy, through a pharmacist or pharmacy personnel, shall do one of the following:
(1) Make available the information described in sub‑subdivisions (a)(1)a. through (a)(1)c. of this section that is consistent with the federal Food and Drug Administration's labeling requirements for opioid pain medication and medication to treat opioid use disorder announced in its Drug Safety Communication dated July 23, 2020.
(2) Post signage in a conspicuous place containing the information described in sub‑subdivisions (a)(1)a. through (a)(1)c. of this section.
(c) Nothing in this section shall be construed to do any of the following:
(1) Limit a practitioner's liability for negligent diagnosis or treatment of a patient, as allowed under applicable State or federal law.
(2) Constitute negligence per se or create a private right of action against any practitioner, including a pharmacy, a pharmacist, or pharmacy personnel, who fails to follow the requirements of this section.
(d) This section shall not apply to the following:
(1) A practitioner providing hospice services as defined in G.S. 131E‑201(5b) to a hospice patient as defined in G.S. 131E‑201(4).
(2) A veterinarian acting in the practice of veterinary medicine, as defined in G.S. 90‑181, at an animal health center, emergency facility, mobile facility, veterinary clinic, or veterinary hospital, as defined in G.S. 90‑181.1.
SECTION 2. This act becomes effective October 1, 2023.